Rozucard

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rozucard

Quick Facts About Rozucard

Property Description
Active ingredient Rosuvastatin calcium
Form Film-coated tablets
Pharmacological class Statin (HMG-CoA reductase inhibitor)
Common use Management of high blood lipid levels (dyslipidemia)
Origin Synthetic drug

What Type of Medication is Rozucard?

Rozucard is a synthetic, single-ingredient prescription medication containing the active substance Rosuvastatin calcium. It belongs to the potent class of drugs known as statins, which function as HMG-CoA reductase inhibitors. The drug is supplied as film-coated tablets designed for oral administration and systemic absorption. Rosuvastatin is classified as a potent synthetic inhibitor used to manage conditions characterized by abnormally high levels of blood fats. This means the compound is chemically manufactured to strongly target the enzyme that controls cholesterol production in the liver.

The General Purpose of Rosuvastatin

The primary purpose of Rosuvastatin therapy is to act as a powerful lipid-lowering agent addressing dyslipidemia and elevated hypercholesterolemia. The drug works to significantly reduce levels of Low-Density Lipoprotein Cholesterol (LDL-C), often referred to as "bad" cholesterol, while concurrently lowering triglycerides and providing a moderate increase in High-Density Lipoprotein Cholesterol (HDL-C), or "good" cholesterol. The general therapeutic goal of Rosuvastatin is to improve the overall lipid profile of patients with elevated cholesterol. The medicine is therefore essential for managing the balance of fats in the bloodstream to support cardiovascular well-being.

How Rosuvastatin Compares to Other Statins

Rosuvastatin is noted for its high efficacy within the statin class, often achieving substantial LDL-C reduction goals. Its chemical composition features a unique hydrophilic structure, which is associated with increased selectivity for the liver, and it exhibits minimal metabolism via the common Cytochrome P450 system. This minimal reliance on a major liver enzyme pathway is a distinguishing feature, differentiating it from certain other statins. This specific profile makes it a key tool in strategies aimed at aggressively improving a patient’s lipid profile.

What side effects are possible with Rozucard?

Possible Side Effects and Safety Information

The safety profile of Rosuvastatin, the active ingredient in Rozucard, is based on classifications defined by government regulatory authorities.

Adverse Reaction Classifications

The most frequently reported adverse reactions are classified as Common, meaning they occurred in a significant percentage of patients during clinical trials. These often involve the Nervous System (e.g., headache) and the Musculoskeletal (e.g., myalgia or muscle pain) and Gastrointestinal Systems (e.g., abdominal pain, nausea). Other reactions, such as arthralgia (joint pain) and asthenia (weakness), are also documented.

Serious Adverse Reactions

The regulatory documents highlight certain serious, less frequent adverse reactions. These include severe skeletal muscle effects like Rhabdomyolysis (severe muscle breakdown) and Myopathy, which require monitoring. Rare but serious Hepatic Dysfunction and fatal and non-fatal hepatic failure are also documented. Additionally, Interstitial Lung Disease and Hypersensitivity Reactions are noted in post-marketing experience.

Safety Considerations and Restrictions

Safety profiles contain important constraints and population-specific considerations. The medication is officially contraindicated in patients with active liver disease, severe renal impairment (creatinine clearance < 30 ml/min), and myopathy. Specific populations, including older adults and Asian patients, may have an increased risk of myopathy, and these factors are formally addressed in the regulatory labeling. Certain effects, such as proteinuria, have been documented as more common at the highest administered dose.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Rosuvastatin (Rozucard) specify that there is no specific antidote or known treatment available in the event of overdosage. Due to this lack of a specific reversal agent, the primary focus of management is on providing symptomatic and supportive measures to mitigate severe, life-threatening toxicities.

Immediate medical attention is required if an overdose is suspected or has occurred. Patients must contact emergency services or a Poison Control Center immediately, as continuous hospital observation may be necessary for management.

The severe complications that necessitate this urgent action primarily involve the musculoskeletal system and renal system. Regulatory information highlights the risk of rhabdomyolysis—severe muscle tissue breakdown—which can lead to acute renal failure. The risk of such severe outcomes is officially noted to be increased in specific populations, including those with severe renal impairment, uncontrolled hypothyroidism, or individuals who are elderly or of Asian descent.

Overdose Management Requirement Official Regulatory Status
Specific Antidote None known
Hemodialysis Efficacy Does not significantly enhance clearance
Mandatory Monitoring Liver function and Creatine Kinase (CK) levels

Regulatory guidance mandates the immediate withdrawal of the drug. Since the drug is not significantly cleared by hemodialysis, the regulatory structure emphasizes immediate supportive care and the rigorous monitoring of both kidney and liver function.

Therapeutic Uses of Rozucard

Main Uses of Rozucard

Rozucard is a medication belonging to the group of drugs known as statins. Its primary purpose is to manage lipid levels in individuals diagnosed with high blood cholesterol. It is typically prescribed when dietary changes and physical exercise alone have proven insufficient to normalize lipid profiles.

Treatment of Hypercholesterolemia

Rozucard is used to treat primary hypercholesterolemia or mixed dyslipidemia in adults and children. In these conditions, the blood contains elevated levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. The medication works by inhibiting a specific enzyme in the liver responsible for cholesterol production, thereby reducing the amount of cholesterol circulating in the bloodstream.

Management of Genetic Cholesterol Conditions

This medication is also utilized in the management of homozygous familial hypercholesterolemia, a rare genetic condition characterized by extremely high cholesterol levels from birth. In such cases, Rozucard may be used alongside other lipid-lowering treatments or when other therapies are unavailable.

Therapeutic Benefits

The primary benefit of Rozucard is the improvement of the overall lipid profile. By modifying the concentrations of fats in the blood, the medication helps maintain a healthier internal environment.

  • Reduction of LDL Cholesterol: It effectively lowers high levels of LDL cholesterol.
  • Reduction of Triglycerides: It assists in decreasing the levels of triglycerides, another type of fat found in the blood that can contribute to health complications.
  • Increase of HDL Cholesterol: The treatment often leads to a modest increase in high-density lipoprotein (HDL) cholesterol, commonly known as "good" cholesterol, which helps remove other forms of cholesterol from the bloodstream.

Long-term Health Impact

By managing lipid levels, Rozucard plays a role in slowing the progression of atherosclerosis, a condition where fatty deposits build up in the arterial walls. In patients with a high risk of cardiovascular events, such as those with existing heart disease or multiple risk factors like diabetes and high blood pressure, the medication is used to reduce the likelihood of serious complications, including heart attacks and strokes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Rozucard (rosuvastatin) is prescribed to adults to help lower high cholesterol and triglyceride levels, and to reduce the risk of serious cardiovascular events like heart attack and stroke. It is typically used as an addition to a diet and exercise program when those alone are insufficient. It is also approved for use in certain pediatric patients (children and adolescents) aged 7 years and older with specific inherited forms of high cholesterol, such as homozygous and heterozygous familial hypercholesterolemia.


Rozucard is not suitable for all individuals. It is contraindicated for those with an allergy to rosuvastatin or any of its components. Patients with active liver disease or unexplained, persistent elevation of liver enzymes should not take this medication. Additionally, it must not be used by pregnant or breastfeeding women due to the potential for harm to the developing baby or infant. Caution is advised, and a lower dose may be required, for patients with severe kidney impairment, those of Asian descent, and those who consume excessive amounts of alcohol.

What should I know about interactions with other medicines?

Rozucard (Rosuvastatin) interacts with other substances primarily through two documented mechanisms: significant modification of systemic exposure and pharmacodynamic synergy related to muscle toxicity.

Documented Pharmacokinetic Interactions

Rosuvastatin clearance is strongly influenced by drug transporters, particularly OATP1B1 and BCRP, not by the common Cytochrome P450 system. Inhibitors of these transporters increase Rosuvastatin plasma concentrations ( AUC). This includes substances such as Cyclosporine and specific Antiviral combinations (e.g., Lopinavir/Ritonavir, Glecaprevir/Pibrentasvir), which lead to mandatory dosage restrictions to mitigate the risk associated with elevated exposure.

Interacting Agent Official Outcome / Restriction
Cyclosporine Markedly increased exposure; maximum dose is restricted to 5 mg once daily.
Antivirals (Specific) Increased exposure; maximum dose is typically restricted to 10 mg once daily.
Aluminum/Magnesium Antacids Decreased absorption; administration must be separated by at least two hours.

Pharmacodynamic Interactions

Co-administration with other agents that carry a risk of skeletal muscle effects can lead to pharmacodynamic synergy, increasing the documented risk of myopathy or rhabdomyolysis. This risk is noted with Gemfibrozil and other Fibrates, requiring strict avoidance or adherence to a 10 mg maximum dose limit for Rosuvastatin. The official labeling also cautions against combining Rosuvastatin with lipid-modifying doses of Niacin (ge 1 g/day) due to this increased risk of muscle adverse effects.

Population-specific interaction considerations exist for Asian patients and individuals with severe renal impairment (CrCl < 30 mL/min), who have lower maximum dosage limitations when taking interacting medicines.

Mechanism of Action

Rozucard acts as a competitive and reversible inhibitor of HMG-CoA reductase, the key enzyme regulating the liver's production of cholesterol via the mevalonate pathway. This targeted blockade of the rate-limiting step in hepatic cholesterol synthesis depletes the internal cholesterol stores of liver cells.

The resulting cholesterol deficit triggers a compensatory cellular response: the significant upregulation of LDL Receptors on the hepatocyte surface. These increased receptors enhance the liver's ability to capture and internally process circulating Low-Density Lipoprotein Cholesterol (LDL-C) particles, leading to systemic clearance of lipids from the bloodstream.

Beyond its primary lipid cascade, the drug exhibits pleiotropic effects by indirectly reducing the synthesis of isoprenoid intermediates. This action modulates vascular signaling pathways, which alters the function of the endothelium (artery lining) and is associated with the modulation of local inflammatory markers.

Dosage and Administration Information

How to Use Rozucard (Rosuvastatin): Administration Guidelines

This section outlines the instructions for the proper administration and dosing of rosuvastatin.


Administration Scope

Instruction Category Guideline
Route and Form Must be taken orally as a film-coated tablet.
Frequency and Timing Take once daily (qDay). It can be taken at any time of day, with or without food.
Dosing Range The dose range is typically 5 mg to 40 mg once daily. The usual starting dose is 10 mg or 20 mg.
Maximum Dose The maximum daily dose is 40 mg. This dose should only be considered for patients who have not achieved their treatment goal on the 20 mg dose.

Procedural Instructions

  • Tablet Handling: Swallow the tablet whole. Do not crush, dissolve, or chew the tablet.
  • Dose Titration: Dosage adjustments should be made based on regular lipid level assessments, typically performed within 2 to 4 weeks after starting the medicine or changing the dose.
  • Missed Dose: If you miss a dose, do not take an extra dose or double the next dose. Simply resume treatment with your next scheduled dose.

Population-Specific Dosing Rules

Specific starting and maximum dose limitations apply to certain patient populations:

  • Severe Renal Impairment (CrCl < 30 mL/min): The starting dose should be 5 mg, and the maximum dose must not exceed 10 mg once daily.
  • Asian Patients: A 5 mg starting dose is recommended due to potentially increased drug concentration. The 40 mg dose is often restricted or contraindicated in this group.

Recent Clinical Evidence

Evidence for Use in Managing High Blood Lipids (Dyslipidemia and Hypercholesterolemia)

Research examined Rozucard (Rosuvastatin) in the context of conditions characterized by abnormally high levels of blood fats. Studies often took the form of short-term Randomized Controlled Trials (RCTs) that explored changes in measured concentrations of LDL-C, Total Cholesterol, and Triglycerides. Findings indicate that a large proportion of participants met the pre-defined lipid target thresholds established by the research protocols. Comparative trials, such as the STELLAR study, explored the measured difference in these biomarker shifts when compared against other statins included in the research. Follow-up durations were limited in these comparative trials when measuring only the initial shift in lipid biomarkers, and long-term comparative evidence on maintenance remains limited.


Evidence for Use in Addressing Cardiovascular Risk

Research explored Rosuvastatin in the context of trials that evaluated the occurrence of major vascular events, such as non-fatal heart attack or stroke. This evidence is primarily derived from large-scale, long-duration, placebo-controlled outcome trials. The major placebo-controlled outcome trial described the measured occurrence rate of the composite event endpoint in the study group and in the placebo group. Evidence suggests that the measured differences in occurrence rates were associated with a corresponding measured change in inflammatory biomarkers like high-sensitivity C-Reactive Protein (hsCRP). Retrospective analyses and some comparative studies explored patterns related to all-cause mortality and MACE when comparing against other treatments, and findings were observed to be mixed across various study types.


Evidence in Specific Patient Populations and Uncertainties

Rosuvastatin was evaluated in specific patient populations, including pediatric patients (children aged 8 years and older) with inherited, severe forms of high cholesterol (Heterozygous Familial Hypercholesterolemia). Research describes patterns related to measured shifts in LDL-C levels in these youth populations. Long-term patterns regarding clinical outcomes are not fully established for all aspects of the research, as certain key primary prevention studies were stopped earlier than planned. Comparative evidence that tracks outcomes across diverse global populations over extended periods is lacking, and certainty remains low regarding the full range of comparative long-term measured changes.

Key Studies & References

  1. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)

Frequently Asked Questions (FAQ)

Common questions about Rozucard (FAQ)

Q: Is Rozucard used to lower both LDL and triglycerides?

A: Yes, official product information indicates that Rozucard is used to reduce elevated levels of Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. It is also indicated to increase High-Density Lipoprotein Cholesterol (HDL-C).

Q: How quickly does Rozucard start to lower cholesterol levels?

A: Regulatory documents do not state the exact time until the maximum therapeutic effect is reached. However, official guidelines recommend that a healthcare professional should assess lipid levels as early as 2 to 4 weeks after starting the medication or adjusting the dosage to monitor the initial results.

Q: What are the most common side effects people report with Rozucard?

A: According to official clinical studies, the most common reported adverse reactions are headache, muscle pain, abdominal pain, and nausea. Other common effects include joint pain and weakness. These effects were frequently reported in patients during the clinical trials.

Q: Can Rozucard cause muscle aches or weakness?

A: Yes, the official product safety profile lists muscle pain (myalgia) and weakness (asthenia) as common adverse reactions. Unexplained or persistent muscle symptoms may be a reason for a healthcare professional to re-evaluate the treatment.

Q: Are there known side effects of Rozucard on the liver?

A: Yes, the medication is contraindicated (not suitable for use) in patients with active liver disease. Furthermore, rare cases of fatal or non-fatal hepatic failure and persistent elevations of liver enzymes have been reported. The potential for these effects is why liver function may be routinely checked during therapy.

Q: Does Rozucard interact with common pain relievers like Tylenol or Advil?

A: The official drug label lists specific prescription drugs with known interactions, but it does not list a major interaction with common over-the-counter pain relievers like Acetaminophen (Tylenol) or Ibuprofen (Advil). For overall safety, it is always recommended to discuss all medications with a healthcare professional.

Q: Do I have to take Rozucard forever once I start?

A: Rozucard therapy is intended to be used as an addition to diet and exercise to control lipid levels. The duration of therapy is not fixed; its continuation depends on regular professional monitoring to ensure that the patient's treatment goal is maintained over time.

Q: Can older adults safely take Rozucard?

A: Official studies indicate that no overall differences in efficacy or safety were observed between older and younger subjects. However, due to potential factors, a lower starting dose may be considered for patients over 70 years of age.

Q: Does Rozucard have any benefits besides lowering cholesterol?

A: Yes, official documents indicate that the medication is prescribed to reduce the risk of major cardiovascular events. The drug is indicated to reduce the risk of major cardiovascular events such as stroke, heart attack, and the need for arterial procedures in high-risk individuals.

Q: Is there research showing Rozucard helps prevent strokes?

A: The medication is indicated to reduce the risk of stroke in certain individuals who meet specific risk criteria, according to clinical trial data described in regulatory documents. This use is based on the drug's established effect on cardiovascular risk.

Q: Will I still need to diet and exercise while taking Rozucard?

A: Official prescribing information describes this medication as an adjunct to (or addition to) a cholesterol-lowering diet and exercise program. It is not intended to be a replacement for these lifestyle changes.

Q: Is it common for Rozucard to cause stomach upset?

A: Official safety data classifies nausea and abdominal pain as common adverse reactions. These effects are classified within the gastrointestinal system.

Q: Are children or teenagers ever prescribed Rozucard?

A: Yes, the medication is indicated for use in certain pediatric patients. Specifically, it can be prescribed to children and adolescents aged 8 to 17 years who have specific severe, inherited forms of high cholesterol known as Familial Hypercholesterolemia.

Q: Can Rozucard cause joint pain or arthritis-like symptoms?

A: Official clinical safety reports list arthralgia, or joint pain, as a common adverse reaction. If musculoskeletal symptoms become severe, it is advisable to discuss them with a healthcare professional.

Q: Can Rozucard affect sleep or cause insomnia?

A: The official product information notes that sleep disturbances, including insomnia (difficulty sleeping) and nightmares, have been observed in post-marketing reports. The exact frequency of these effects is not officially known.

Q: Are there studies on the long-term safety of Rozucard?

A: While some primary prevention trials were concluded early, official regulatory documents describe long-term safety data from certain studies. These studies have tracked patients for an extended duration, in some cases up to 96 weeks.

Q: Is Rozucard used for people with familial hypercholesterolemia?

A: Yes, the medication is indicated for use in adult patients who have a specific, severe inherited form of high cholesterol called Homozygous Familial Hypercholesterolemia (HoFH). It is also used in pediatric patients with this condition.

Q: Are there any skin-related side effects from Rozucard?

A: Official safety documents indicate that hypersensitivity reactions have been reported. These reactions can include skin issues such as rash, itching (pruritus), hives (urticaria), and swelling (angioedema).

Q: Does taking Rozucard protect against developing heart disease?

A: The medication is officially indicated to reduce the risk of major cardiovascular events like heart attack and stroke. The reduction in risk contributes to overall cardiovascular disease management in at-risk patients.

Q: Is it normal to feel tired when you first start taking Rozucard?

A: Official safety data lists asthenia, or weakness, as a common adverse reaction. While the timing of the effect is not specified, common reactions are those most frequently reported by patients.

Q: Is Rozucard safe for people who have kidney issues?

A: For patients with severe renal impairment (a low creatinine clearance rate), official guidelines require a lower starting dose and a restricted maximum daily dose. This indicates that specific medical management, including potential dose adjustment, is required for this population.

Q: How is Rozucard different from other medicines that treat high cholesterol?

A: Rozucard is unique within the statin class because its breakdown and clearance in the body do not significantly rely on the major CYP450 3A4 liver enzyme pathway. This difference in metabolism helps distinguish it from certain other statin medications.

Q: How long does it take to see the full benefit of Rozucard?

A: Although the time to full maximum therapeutic effect is not stated, official guidelines require that lipid levels be assessed as early as 2 to 4 weeks after starting the drug. This allows for prompt monitoring and potential dosage adjustments.

Q: Is it safe to drink alcohol in moderation while taking Rozucard?

A: Official information advises against drinking large amounts of alcohol while on this medication. Official information does not define 'moderate' consumption; however, alcohol abuse is a risk factor for skeletal muscle effects associated with statins.

Q: Does Rozucard interact with oral contraceptives (birth control pills)?

A: Yes, coadministration of this medication may increase the plasma concentrations of certain hormones found in oral contraceptives. Regulatory documents state that patients of reproductive potential should be counselled on the use of effective contraception during treatment.

Q: Does Rozucard help with inflammation?

A: Research indicates that the medication has been evaluated in patients with elevated high-sensitivity C-Reactive Protein (hsCRP), which is an inflammatory marker. While it is not indicated as an anti-inflammatory drug, the primary prevention indication suggests a connection to managing inflammation-related risk factors.

Q: What's the difference between HDL and LDL cholesterol, and how does Rozucard affect them?

A: Rozucard is indicated to reduce Low-Density Lipoprotein Cholesterol (LDL-C), which is associated with cardiovascular risk. It also works to increase High-Density Lipoprotein Cholesterol (HDL-C), which helps remove excess cholesterol from the bloodstream.

Q: What happens if my cholesterol gets too low while on Rozucard?

A: If lipid levels fall below the clinically defined target range, regulatory guidelines advise a healthcare professional to consider a decrease in the medication's dose.

Q: Why do some people stop taking Rozucard?

A: Reasons for discontinuing treatment can include developing active liver disease or sustained abnormal liver enzyme levels. Additionally, if a patient experiences unexplained or persistent symptoms like muscle pain, tenderness, or weakness, the medication may be stopped under medical supervision.

Q: Does Rozucard interact with herbal supplements like St. John's Wort?

A: The drug label lists specific drug interactions but does not specifically name St. John's Wort. However, general caution is advised, and patients should always discuss all concomitant medicines and supplements with their healthcare professional.

Q: Do any vitamins or supplements interact with Rozucard?

A: The official drug interaction section focuses on prescription drugs and certain antacids. While no specific vitamins are listed as major interactions, patients are generally advised to discuss all supplements they take with their healthcare professional.

How should Rozucard be stored and disposed of?

The official regulatory requirements for Rosuvastatin (Rozucard) storage and disposal ensure product stability and safety.

Storage Conditions

Rosuvastatin tablets must be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original package and protected from environmental factors like moisture and temperatures exceeding 30 C. To prevent accidental access, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Rozucard should be discarded promptly when no longer needed or when the expiration date is reached. Disposal must follow local pharmaceutical waste requirements; the tablets must not be thrown into household trash or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rozucard found in:

A-Z Index: